In English | En español
Questions About Cancer? 1-800-4-CANCER

Cannabis and Cannabinoids (PDQ®)

  • Last Modified: 11/06/2014

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document

Changes to This Summary (11/06/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information

Added text to state that a growing number of pediatric patients are seeking symptom relief with Cannabis or cannabinoid treatment, although studies are limited.


Revised the Table with changes to include Massachusetts, Minnesota, and New York to the list of localities that permit the use of Cannabis for certain medical conditions.

Added Pertwee et al. as reference 12.

Added text to state that nabiximols is also approved in Canada for symptomatic relief of pain in multiple sclerosis and advanced cancer.

Laboratory/Animal/Preclinical Studies

Added text to state that other studies have also shown the antitumor effect of cannabinoids in preclinical models of breast cancer (cited Caffarel et al. as reference 19 and McAllister et al. as reference 20).

Added text to state that cannabidiol together with delta-9-tetrahydrocannabinol may enhance the antitumor activity of classic chemotherapeutic drugs such as temozolomide in some mouse models of cancer (cited Torres et al. as reference 32).

This summary is written and maintained by the PDQ Cancer Complementary and Alternative Medicine Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.